These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 22795807

  • 21. Calcineurin inhibitors and rapamycin: cancer protection or promotion?
    Weischer M, Röcken M, Berneburg M.
    Exp Dermatol; 2007 May; 16(5):385-93. PubMed ID: 17437481
    [Abstract] [Full Text] [Related]

  • 22. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 23. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P, Rostaing L.
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [Abstract] [Full Text] [Related]

  • 24. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 25. Combination of immunosuppressive drugs leaves specific "fingerprint" on gene expression in vitro.
    Rumberger B, Kreutz C, Nickel C, Klein M, Lagoutte S, Teschner S, Timmer J, Gerke P, Walz G, Donauer J.
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):283-92. PubMed ID: 19235537
    [Abstract] [Full Text] [Related]

  • 26. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 27. Spontaneous DNA repair in human mononuclear cells is calcium-dependent.
    Ori Y, Herman M, Chagnac A, Malachi T, Gafter U, Korzets A.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):842-6. PubMed ID: 16157301
    [Abstract] [Full Text] [Related]

  • 28. Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
    Konno O, Hirano T, Katsuyama K, Oka K, Matsuno N, Nagao T.
    Transpl Immunol; 2007 Apr 28; 17(3):187-92. PubMed ID: 17331845
    [Abstract] [Full Text] [Related]

  • 29. Everolimus: a guide to its use in liver transplantation.
    Keating GM, Lyseng-Williamson KA.
    BioDrugs; 2013 Aug 28; 27(4):407-11. PubMed ID: 23696253
    [Abstract] [Full Text] [Related]

  • 30. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
    Wowro SJ, Schmitt KRL, Tong G, Berger F, Schubert S.
    Int Immunopharmacol; 2016 Jan 28; 30():9-17. PubMed ID: 26613512
    [Abstract] [Full Text] [Related]

  • 31. Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients.
    Tanaka S, Nakajima K, Hirano T, Oka K, Saito T, Wakata N.
    J Pharm Pharmacol; 2008 Oct 28; 60(10):1341-6. PubMed ID: 18812027
    [Abstract] [Full Text] [Related]

  • 32. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Oct 28; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 33. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.
    Eberhardt W, Nasrullah U, Pfeilschifter J.
    Cell Signal; 2018 Dec 28; 52():1-11. PubMed ID: 30145216
    [Abstract] [Full Text] [Related]

  • 34. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct 28; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 35. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
    Forgacs B, Merhav HJ, Lappin J, Mieles L.
    Transplant Proc; 2005 May 28; 37(4):1912-4. PubMed ID: 15919502
    [Abstract] [Full Text] [Related]

  • 36. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells.
    Schroecksnadel S, Sucher R, Kurz K, Fuchs D, Brandacher G.
    Transpl Immunol; 2011 Sep 28; 25(2-3):119-23. PubMed ID: 21742032
    [Abstract] [Full Text] [Related]

  • 37. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 38. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells.
    Lehle K, Schreml S, Kunz-Schughart LA, Rupprecht L, Birnbaum DE, Schmid C, Preuner JG.
    J Vasc Res; 2008 Aug 27; 45(4):333-42. PubMed ID: 18319592
    [Abstract] [Full Text] [Related]

  • 39. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ.
    Transplantation; 2013 Jan 15; 95(1):184-91. PubMed ID: 23222818
    [Abstract] [Full Text] [Related]

  • 40. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 15; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.